Product
WTX212
1 clinical trial
1 drug
3 indications
Indication
CancerIndication
Solid TumorIndication
hematologic malignanciesDrug
WTX212Clinical trial
A Multicenter, Single-arm, Open-label, Dose-escalation and Dose-expansion Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell WTX212 in Patients With Advanced MalignanciesStatus: Recruiting, Estimated PCD: 2023-12-31